Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
emtricitabine or lamivudine
- Development stage
- Approved
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Emtricitabine and lamivudine are both nucleoside reverse transcriptase inhibitors (NRTIs) used as antiretroviral agents in the treatment of human immunodeficiency virus (HIV) infection. They are also active against hepatitis B virus (HBV). Both drugs work by inhibiting the reverse transcriptase enzyme, which is essential for viral replication in HIV and HBV. Emtricitabine is marketed under the brand name Emtriva, while lamivudine is available as Epivir, Epivir-HBV, and other names. These medications are always used in combination with other antiretroviral drugs to prevent resistance and improve efficacy. Neither drug cures HIV or HBV but helps reduce viral load, delay disease progression, and lower transmission risk[1][2][3][4].
- Brand names
- EmtrivaEpivirEpivir A/FEpivir HBV3tcHeptovir
- Other names
- FTC (for emtricitabine)3TC (for lamivudine)
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseHBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on emtricitabine or lamivudine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on emtricitabine or lamivudine.